Company profile: Marea Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology therapies leveraging human genetics to develop next-generation treatments for cardiometabolic diseases. Pipeline includes MAR001, a monoclonal antibody targeting ANGPTL4 to reduce remnant cholesterol and triglycerides and improve adipose tissue function (Phase 2), MAR002, an anti-growth hormone receptor antibody for acromegaly, and undisclosed discovery programs.
Products and services
- MAR001 (ANGPTL4 mAb): A Phase 2 clinical-stage monoclonal antibody targeting ANGPTL4 that reduces remnant cholesterol and triglycerides and improves adipose tissue function in patients at cardiovascular disease risk
- MAR002: A receptor-targeted anti–growth hormone receptor antibody engineered and under development for acromegaly treatment in affected patients, as an antibody-based therapeutic directed at the growth hormone receptor
- Future Pipeline: A genetics-driven set of undisclosed discovery programs leveraging human genetics to architect next-generation medications for cardiometabolic diseases, oriented toward therapy development across cardiometabolic illness targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Marea Therapeutics
Essential Medical
HQ: United States
Website
- Description: Provider of femoral artery closure devices to seal femoral punctures following vascular access medical procedures requiring a cardiac catheterization. The company has developed two devices, including MANTA, designed to close large-bore punctures (10–24F) after procedures such as transcatheter aortic valve replacement (TAVR) and abdominal aortic aneurysm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Essential Medical company profile →
FlowCardia
HQ: United States
Website
- Description: Provider of catheter-based medical device technologies that facilitate guidewire crossing and treatment of totally occluded coronary and peripheral arteries (Chronic Total Occlusions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowCardia company profile →
Micell Technologies
HQ: United States
Website
- Description: Provider of biomedical device solutions focused on developing interventional cardiology systems for vascular drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micell Technologies company profile →
Impella
HQ: Germany
Website
- Description: Provider of minimally invasive cardiovascular support systems for numerous indications in cardiology and coronary surgery. Based in Aachen, Germany, the company develops, manufactures and markets its technology, which is protected by more than 30 European and international patents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impella company profile →
Huyabio
HQ: United States
Website
- Description: Provider of novel biopharmaceutical product opportunities, including HBI-8000, an oral class I selective HDAC inhibitor for cancers; HBI-3000, a multi-ion channel blocker for atrial fibrillation; HBI-2376, an SHP2 inhibitor for solid tumors; HBI-ONC, an epigenetic inhibitor for MDS/AML; and HBI-3800, a small molecule to regenerate cardiac muscle damaged by ischemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Huyabio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Marea Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Marea Therapeutics
2.2 - Growth funds investing in similar companies to Marea Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Marea Therapeutics
4.2 - Public trading comparable groups for Marea Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →